Orforglipron does not yet have an approval date, as it is still under clinical development.
What is Orforglipron's Development Status?
Orforglipron is an investigational oral non-peptide small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. It is being developed for the treatment of obesity and type 2 diabetes [1]. As of late 2023, Orforglipron was in Phase 2 clinical trials [1][2].
When Might Orforglipron Be Approved?
The timeline for regulatory approval depends on the successful completion of ongoing clinical trials and the subsequent submission and review of data by regulatory agencies like the U.S. Food and Drug Administration (FDA). Specific approval dates are not yet available.
What are the Next Steps for Orforglipron?
Following successful Phase 2 trials, Orforglipron would need to advance into Phase 3 trials, which are larger, more complex studies designed to confirm efficacy and monitor side effects in a broad patient population. Positive Phase 3 results are a prerequisite for seeking regulatory approval [1].
How Does Orforglipron Work?
Orforglipron mimics the action of the natural hormone GLP-1. GLP-1 plays a role in regulating appetite, glucose metabolism, and insulin secretion. By activating GLP-1 receptors, Orforglipron aims to reduce food intake and improve glycemic control [1].
Who is Developing Orforglipron?
Orforglipron is being developed by Eli Lilly and Company [1].
What is the Clinical Trial Data for Orforglipron?
Early clinical data from Phase 1 and Phase 1b studies showed that Orforglipron led to significant weight loss and improvements in blood sugar levels. Participants in these studies experienced an average weight reduction of up to 10% [1][2].
Are There Other Oral GLP-1 Agonists Available?
While injectable GLP-1 receptor agonists have been available for some time, the development of effective oral GLP-1 receptor agonists has been a significant area of research. Orforglipron represents a novel approach to oral delivery for this class of medication [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/orforglipron
[2] https://www.drugpatentwatch.com/drugs/orforglipron/clinical-trials